|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Ariad_Pharmaceuticals
gptkb:Medi_Gene_AG
gptkb:Gleevec
gptkb:Novartis_Foundation
|
|
gptkbp:acquisition
|
gptkb:Ave_Xis
gptkb:The_Medicines_Company
gptkb:Ziarco_Pharma
gptkb:Alcon
gptkb:Chiron_Corporation
gptkb:Alcon_(2010)
|
|
gptkbp:advertising
|
gptkb:Marie-France_Tschudin
|
|
gptkbp:ceo
|
gptkb:Vas_Narasimhan
|
|
gptkbp:clinical_trial
|
invests in innovative therapies
conducts clinical trials globally
focuses on rare diseases
focuses on CAR-T therapies
focuses on gene therapies
focuses on patient-centric research
|
|
gptkbp:collaborations
|
collaborates with academic institutions
|
|
gptkbp:employees
|
approximately 110,000
around 110,000
|
|
gptkbp:founded
|
gptkb:1996
|
|
gptkbp:global_presence
|
operates in over 140 countries
|
|
gptkbp:has_transformation
|
gptkb:Joaquin_Duato
|
|
gptkbp:headquarters
|
gptkb:Basel,_Switzerland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Novartis AG
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:invention
|
holds numerous patents
|
|
gptkbp:investment
|
listed on the Swiss Stock Exchange
|
|
gptkbp:is_divided_into
|
gptkb:Sandoz
Innovative Medicines
|
|
gptkbp:language_of_instruction
|
strong drug pipeline
|
|
gptkbp:leadership
|
diverse leadership team
|
|
gptkbp:market
|
global market
|
|
gptkbp:market_cap
|
approximately $200 billion (2021)
|
|
gptkbp:part_of
|
gptkb:Dow_Jones_Industrial_Average
|
|
gptkbp:partnership
|
gptkb:temple
gptkb:Johnson_&_Johnson
gptkb:Takeda_Pharmaceutical_Company
gptkb:physicist
gptkb:Sanofi
gptkb:Bristol-Myers_Squibb
gptkb:Microsoft
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Eli_Lilly_and_Company
gptkb:Abb_Vie
gptkb:Celgene
gptkb:Regeneron
GSK (Glaxo Smith Kline)
|
|
gptkbp:philanthropy
|
gptkb:Novartis_Foundation
|
|
gptkbp:products
|
generic drugs
vaccines
biopharmaceuticals
prescription medications
|
|
gptkbp:research
|
gptkb:Jay_Bradner
|
|
gptkbp:research_areas
|
has multiple research centers worldwide
|
|
gptkbp:research_focus
|
oncology
neuroscience
immunology
cardiovascular
|
|
gptkbp:revenue
|
$48.5 billion (2020)
|
|
gptkbp:social_responsibility
|
engages in CSR initiatives
|
|
gptkbp:stock_exchange
|
gptkb:NYSE
|
|
gptkbp:subsidiary
|
gptkb:Sandoz
|
|
gptkbp:sustainability
|
committed to sustainable practices
|
|
gptkbp:symbol
|
NVS
|
|
gptkbp:traded_on
|
gptkb:New_York_Stock_Exchange
|